Table 1 Parameters, methods and equipment used in the study
From: Cardiovascular risk and the COVID-19 pandemic: a population-based and case‒control studies
Parameter | Method | Device |
|---|---|---|
Fasting glucose and the 120 min glucose in oral glucose tolerance test (OGTT) | hexokinase method | Cobas s111, ROCHE Diagnostic Ltd., Rotkreuz, Switzerland |
Haemoglobin A1c (HbA1c) | ion-exchange high-performance liquid chromatography (HPLC) | Bio-Rad, Hercules, CA, USA |
Total cholesterol (TC) | enzymatic colorimetric method | Cobas s111, ROCHE Diagnostic Ltd., Rotkreuz, Switzerland |
High-density lipoprotein cholesterol (HDL-c) | enzymatic colorimetric method | Cobas s111, ROCHE Diagnostic Ltd., Rotkreuz, Switzerland |
Low-density lipoprotein cholesterol (LDL-c) | enzymatic colorimetric method | Cobas s111, ROCHE Diagnostic Ltd., Rotkreuz, Switzerland |
Triglycerides (TG) | enzymatic colorimetric method | Cobas s111, ROCHE Diagnostic Ltd., Rotkreuz, Switzerland |
Anti-nucleocapsid-IgG antibody (anti-N IgG) | electrochemiluminescence method (ECLIA) | Cobas e411, ROCHE Diagnostic Ltd., Rotkreuz, Switzerland |
Creatinine | enzymatic colorimetric method | Cobas s111, ROCHE Diagnostic Ltd., Rotkreuz, Switzerland |
Blood pressure (BP) | oscillometric method | Omron Healthcare Co. Ltd. MG Comfort device |
Body composition | dual-energy X-ray absorptiometry (DEXA) | GE Healthcare, Chicago, IL, USA |